The V3 loop in the envelope (Env) of HIV-1 is one of the major targets of neutralizing antibodies. However, this antigen is hidden inside the Env trimer in most isolates and is fully exposed only during CD4-gp120 interaction. Thus, primary HIV-1 isolates are relatively resistant to anti-V3 antibodies because IgG is too large to access the V3 loop. To overcome this obstacle, we constructed singlechain variable fragments (scFvs) from anti-V3 monoclonal antibodies 0.5g, 5G2, and 16G6. Enhanced neutralization by 0.5g and 5G2 scFvs was observed in strains resistant to their IgG counterparts. Neutralization coverage by 0.5g scFv reached up to 90z of the tested viruses (tier 2 and 3 classes). The temperature-regulated neutralization assay revealed that extensive cross-neutralization of 0.5g scFv can be explained by post-attachment neutralization. Neutralization assay involving viruses carrying an intersubunit disulfide bond (SOS virus) showed that the neutralization-susceptible timeframe after attachment was 60 to 120 min. These results indicate that the scFvs efficiently access the V3 loop and subsequently neutralize HIV-1, even after virus attachment to the target cells. Based on its broad and potent neutralizing activity, further development of anti-V3 scFv for therapeutic and preventive strategies is warranted.
INTRODUCTION
The neutralizing antibody (NAb) response against human immunodeficiency virus type 1 (HIV-1) is crucial for protection from HIV-1 infection (1,2) The HIV-1 envelope glycoprotein (Env), consisting of 2 subunits, namely, gp120 and gp41, is the principal target of NAbs (3) . To initiate infection, 2 gp120 regions need to engage with the cell surface proteins of target cells: the CD4-binding site (CD4bs) and the chemokine receptor-binding site. The latter consists of regions in the V3 loop and the bridging sheet, which includes the b20 and b21 strands of C4 and the b2 and b3 strands of the V1/V2 stem (4) (5) (6) (7) . While the V3 loop plays an essential role in the infectivity and co-receptor usage of the virus, it is also one of the major targets of NAbs observed in HIVinfected individuals (7) (8) (9) (10) and in subjects immunized with candidate HIV vaccines (7, (10) (11) (12) .
Some anti-V3 antibodies have been shown to undergo cross-reactive neutralization that includes tier 2 isolates (13) (14) (15) and have induced significant viral load suppression when administered in vivo (16) . However, most of the anti-V3 Abs only neutralize tier 1 viruses, and they poorly neutralize primary isolates with a tier 2 phenotype (17) . The V3 epitope is hidden within the Env trimer in most primary HIV-1 isolates, because of masking by V1/V2 loops and carbohydrates in non-triggered Env (18, 19) The interaction between gp120 and CD4, which initiates HIV-1 entry, induces conformational changes in the Env trimer, followed by exposure of the V3 loop between the gp120 and the target cell membrane (6, 7) . However, it is difficult for anti-V3 antibodies to bind to their epitope following CD4-gp120 interaction because IgG, with an average size of 115 Å, is too large to achieve the close physical proximity to gp120 and cellular membrane, which is required for access to the V3 loop (20) . The distance between the bound HIV-1 gp120 and the target cell membrane is estimated to be 45-80 Å.
In a previous study, Labrijn et al., reported that the single-chain variable fragments (scFvs) of the monoclonal antibodies (MAbs) to CD4-induced (CD4i) epitopes (CD4i antibodies) better neutralize tier 2 isolates that were not neutralized by the full IgG versions of the CD4i antibodies (20) . The scFv is an antibody fragment composed of a variable heavy chain (VH) and a variable light chain (VL), connected by a flexible amino acid linker (21, 22) . The average size of an scFv is estimated to be approximately 40 Å. These data suggest that a reduction in the size of the antibody molecule allowed the scFv to access the CD4i epitope after attachment of the virus with the target cell (20) .
We recently reported a panel of MAbs directed against V3, CD4bs, and CD4i epitopes, obtained from an HIV-1-infected individual, which showed complementary and synergistic neutralizing activity against a cross-subtype panel of HIV-1 isolates (11) . In this study, we constructed the scFv counterparts of 3 representative anti-V3 MAbs from the MAb panel and analyzed the binding and neutralizing activities of these scFv against a series of HIV-1 primary isolates, including transmit-ted/founder (T/F) viruses. We observed potent and highly cross-reactive neutralization activity for the scFv from 0.5g MAb. We further elucidated the contribution of the scFv post-attachment neutralization mechanism toward its unexpected high activity in vitro.
MATERIALS AND METHODS
Cells and viruses: TZM-bl (23) (24) (25) (26) (27) (34) and 10 mg of an env-deficient HIV-1 backbone vector pSG3DEnv (11) . Pseudovirus-containing culture supernatants were harvested 48 h post-transfection, filtered through 0.45-mm filters, and stored at -809 C until use. Plasmids from the T/F viruses, namely, pWITO.c/2474, pCH058.c/2960, pRHPA.c/2635, pTRJO.c/2851, pCH040.c/2625, and pCH077.t/2627 (11), were used to produce infectious viruses following the transfection protocol described above. To obtain SOS JR-FL virus, a plasmid expressing JR-FL Env with an SOS mutation (A501C, T605C, and R709 * ) designated as pCXN-SOS JR-FL , was constructed using site-directed mutagenesis by the method described by Binley et al. (35) . The SOS mutation confers a disulfide bond between the C-terminal region of gp120 (A501C) and the gp41 ectodomain (T605C). The plasmid pCXN-SOS JR-FL L175P was constructed by replacing the Apa I-EcoRV fragment from the plasmid expressing JR-FL L175P with the corresponding region of SOS JR-FL plasmid.
Construction of anti-V3 antibody fragments: Plasmids expressing 0.5g or 16G6 IgG were previously constructed from B cell lines producing the monoclonal antibodies 0.5g or 16G6, respectively (11) . Plasmids expressing 5G2 Fab were constructed using a pComb3X vector and the immunoglobulin genes amplified from the B cell line producing 5G2 IgG (11) . The VH and VL regions were amplified from cDNA by PCR using Platinum Taq DNA Polymerase High Fidelity (Life Technologies) and the following primers: 5G2 VH: HFabVH35-F (5 ? -GCT GCC CAA CCA GCC ATG GCC GAG GTG CAG CTG GTG SAG TCT GG-3 ? ) and HFabVHJa-B (5?-CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC GGT GAC CAG GGT TCC-3 ? ); and 5G2 VL: HSCK3-F (5?-GGG CCC AGG CGG CCG AGC TCG TGW TGA CRC AGT CTC C-3 ? ) and HCK5-B (5 ? -GAA GAC AGA TGG TGC AGC CAC AGT-3?). The heavy chain constant domain 1 (CH1) and light chain constant domain (CL) were amplified using pComb3XTT and the following primers: CH1: HIgGCH1-F (5?-GCC TCC ACC AAG GGC CCA TCG GTC-3 ? ) and dpseq (5 ? -AGA AGC GTA GTC CGG AAC GTC-3?); and CL: HKC-F (5?-ACT GTG GCT GCA CCA TCT GTC-3 ? ) and lead-B (5 ? -GCC ATG GCT GGT TGG GCA GC-3 ? ). After purification using a QIAquick Gel Extraction Kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions, the VH-CH1 and VL-CL fragments were constructed from the VH and CH1 or the VL and CL fragments by overlap extension PCR using the following primers: VH-CH1: LeadVH (5?-GCT GCC CAA CCA GCC ATG GCC-3 ? ) and dpseq; and VL-CL: RSC-F (5 ? -GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC-3?) and lead-B. The purified VH-CH1 and VL-CL fragments were connected by overlap extension PCR using the primers RSC-F and dp-EX (5 ? -GAG GAG GAG GAG GAG GAG AGA AGC GTA GTC CGG AAC GTC-3 ? ) and inserted into a pComb3X vector after digestion with SfiI. The plasmid expressing 5G2 IgG was constructed from the 5G2 Fab expression plasmid as previously described (36) . The plasmid expressing 0.5g Fab was constructed as previously described (11) . Plasmids expressing 0.5g or 5G2 scFv were constructed using pComb3X vectors. The heavy and light variable regions were amplified using the following primers: 0.5g scFv VH: HSCVH3a-FL (5 ? -GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG GTG CAG CTG KTG GAG TCT G-3?) and HSCG1234-B (5 ? -CCT GGC CGG CCT GGC CAC TAG TGA CCG ATG GGC CCT TGG TGG ARG C-3 ? ); 0.5g scFv VL: HSCK24-F (5 ? -GGG CCC AGG CGG CCG AGC TCG TGA TGA CYC AGT CTC C-3?) and HSCJK14o-B (5?-GGA AGA TCT AGA GGA ACC ACC TTT GAT YTC CAC CTT GGT CCC-3?); 5G2 scFv VH: HSCVH35-FL (5?-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG GTG CAG CTG GTG SAG TCT GG-3?) and HSCG1234-B; and 5G2 scFv VL: HSCK1-F (5 ? -GGG CCC GGC GGC CGG CTC CGT GCC CGT CTC C-3?) and HSCJK2o-B (5 ? -GGA AGA TCT AGA GGA ACC ACC TTT GAT CTC CAG CTT GGT CCC-3 ? ). The PCR products were connected by overlapping PCR using the primers HSCK24-F and HSCG1234-B for 0.5g scFv or HSCK1-F and HSCG1234-B for 5G2 scFv and inserted into pComb3X vectors after digestion with SfiI. The resultant scFv genes consisted of VH and VL genes, with an 18-amino acid linker (SSGGGGSGGGGGGSSRSS) between them, and both His-tag and HA-tag at the Cterminus.
The 0.5g and 5G2 scFv genes in the pComb3X vectors were transferred to pETCF, a modified pET-22b (＋) with a FLAG-tag at the 3? region of the XhoI site, for efficient scFv production. The 0.5g and 5G2 scFv DNA fragments, which included a His-tag and a HA-tag, were amplified using the following primers: 0.5g: 1C10 VL-F (5 ? -AGA AGG AGA TAT ACA TAT GGC CGA TAT TGT GAT GAC T-3?) and HAIF-R (5?-TCA TCC TTG TAG TCC TTA CTA AGA AGC GTA GTC-3 ? ); or 5G2: 5G2VL-F (5 ? -AGA AGG AGA TAT ACA TGG CCC AGG CGG CCG AG-3?) and HAIF-R. The PCR products were inserted into pETCF, which was digested with NdeI and XhoI using GeneArt Seamless Cloning and Assembly (Life Technologies).
The 16G6 scFv DNA fragment was amplified using a 16G6 IgG expression plasmid as a template and the following primers: scFv167BL-F (5 ? -AGA AGG AGA TAT ACA TAT GGC CTC CTA TGT GST G-3 ? ) and 16G6 VH-R (5?-TAT ACT AGT GAC CGA TGG GCC CTT GGT GGA-3 ? ). The amplified scFv gene fragments were inserted into the 0.5g scFv expression plasmid after digestion with NdeI and SpeI. The scFv genes in the prepared plasmids were confirmed by sequencing.
Expression and purification of anti-V3 scFvs: The plasmids expressing scFv were transformed into Escherichia coli Rosetta 2 (DE3) (Merck, Darmstadt, Germany). A single colony of transformed cells was inoculated in 3 ml of Luria-Bertani (LB) broth containing 100 mg/ml carbenicillin and incubated overnight at 379 C with shaking conditions (200 rpm). The overnight culture was transferred into 250 ml of LB broth containing carbenicillin and further incubated overnight at 379 C with shaking. Production of scFv was induced with 2 mM isopropyl-b-D(-)-thiogalactopyranoside (IPTG) (Wako, Osaka, Japan), and the cultures were incubated at 379 C for 3 h. Cells were harvested by centrifugation at 6,500 rpm for 30 min, and the pellet was sonicated using Sonifier 250A (Branson, Danbury, CT, USA). The inclusion body was washed with phosphatebuffered saline (PBS, pH 7.4) with 0.1z Triton X-100 and was solubilized in PBS containing 6 M guanidine hydrochloride (Gu-HCl) (Wako) overnight at room temperature. To remove insoluble proteins, the solubilized solution was centrifuged at 12,000 rpm for 30 min, and the solution containing denatured scFv was loaded onto a His 60 Ni Superflow Resin column (Clontech, Mountain View, CA, USA). The Ni column was washed with 6 M Gu-HCl in PBS (pH 7.4) and 40 mM imidazole, and the denatured scFv protein was eluted with 6 M Gu-HCl in PBS (pH 7.4) and 500 mM imidazole. The eluted scFv protein was packed into a Spectra/Por dialysis membrane (Spectrum Laboratories, Rancho Dominguez, CA, USA) for refolding. The concentration of Gu-HCl was slowly decreased stepwise, from 6 M to 3 M to 1 M to 0.5 M to 0.25 M to 0.125 M to 0 M, by dialysis for 12 h at 49 C. The refolded scFv protein was loaded onto a column in which the V3 peptide (NNT-20 JR-FL: NNTRKSIHIGPGRAFYTTGE) was bound with SulfoLink coupling resin (Thermo-Fisher, Waltham, MA, USA). The V3 peptide column was washed with PBS (pH 7.4), and the scFv protein was eluted with Glycine-HCl buffer (pH 2.3) at 49 C. The buffer was changed to PBS (pH 7.4) by dialysis. The obtained 5G2 and 16G6 scFvs were used for further analyses. The 0.5g scFv was additionally purified by size exclusion chromatography using a HiLoad 16/60 Superdex 75 prep grade column (GE Healthcare, Buckinghamshire, UK) equilibrated with PBS (pH 7.4).
SDS-PAGE and western blotting: Samples from each step of the purification process were treated with 2 × Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) with or without b-mercaptoethanol (b-ME) and boiled for 5 min. The cell lysates were loaded on a SuperSep Ace 12z SDS-PAGE gel (Wako), and electrophoresis was performed at 190 V for 70 min. Proteins were stained using Bio-Safe Coomassie blue G-250 (BioRad). For Western blotting analysis, the proteins separated by SDS-PAGE were subsequently blotted onto an Immuno-Blot PVDF Membrane for Protein (Bio-Rad). The membrane was blocked with TBST (0.05 M TrisHCl, 0.138 M NaCl [pH 7.4] with 0.05z Tween 20) containing 1z bovine serum albumin for 1 h at 49 C and incubated with rat anti-HA-peroxidase high affinity antibody (3F10; Roche, Mannheim, Germany) overnight at 49 C. The proteins were detected using TMB Membrane peroxidase substrate (Kirkegaard & Perry Laboratories [KPL], Gaithersburg, MD, USA) and were analyzed by Image Quant LAS 4000 (GE Healthcare).
Surface plasmon resonance analysis: The binding activity of IgG, Fab, and scFv was determined by surface plasmon resonance (SPR) analysis using the Biacore 2000 system (GE Healthcare). Biotinylated V3 peptide (biotin-JR-FL-C22) from HIV-1 JR-FL (biotin-NNTRKSIHIGPGRAFYTTGEIC) was immobilized on a sensor chip SA (GE Healthcare) coated with streptavidin. All IgG and antibody fragment samples were dialyzed with HBS-EP (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005z Surfactant P20 [pH 7.4]; GE Healthcare) and were diluted in HBS-EP buffer before being injected into Biacore 2000. The samples were injected at a flow rate of 100 ml/min over a concentration ranging from 0 to 100 nM at 259 C. The equilibrium dissociation constant (K D ) was determined using the Biacore 2000 evaluation software.
Determination of neutralization activity: (i) Standard neutralization assay: The neutralization activity of the monoclonal antibodies and scFvs was evaluated using TZM-bl cells, as described previously (11) . Briefly, serial dilutions of antibody and virus (400; 50z Tissue Culture Infectious Dose) were pre-incubated for 1 h at 379 C in 96-well tissue culture plates. TZMbl cell suspensions containing Polybrene (50 mg/ml) in DMEM with 10z FCS were added to each well. After incubation for 48 h at 379 C with 5z CO 2 , the wells were washed once with PBS and lysed with lysis buffer, and the lysate was transferred to an opaque white plate containing b-galactosidase substrate (Galacto-Star System; Life Technologies). The plate was incubated for 1 h with protection from light. The b-galactosidase activity was measured using a Centro XS 3 LB960 luminometer (Berthold Technologies, Bad Wildbad, Germany). The reduction in infectivity was determined by comparing the relative light units (RLU) in the presence and absence of antibody and was expressed as percentage of neutralization. The half maximal (50z) inhibitory concentration (IC 50 ) was calculated using nonlinear regression and defined as the concentration that caused 50z reduction in luciferase activity. The fold change was calculated as follows: IC 50 of IgG/IC 50 of scFv.
(ii) Temperature-regulated neutralization (TRN) assay: The post-attachment neutralization assays were performed as described previously (20) . Briefly, TZM-bl cells were plated in 96-well cell culture plates and incubated overnight for attachment. After incubation, pseudoviruses corresponding to the titer yielding about 200,000 RLU were added with Polybrene (50 mg/ml) and incubated at 49 C for 1 h. The unbound viruses were removed by washing twice with PBS. Finally, serial dilutions of IgGs and scFvs in DMEM with 10z FCS were Fig. 1 . Expression and purification of scFvs. Samples from each step of the purification of 0.5g scFv were analyzed using SDS-PAGE (A) and Western blotting (B). The 0.5g scFv protein was expressed in E. coli strain Rosetta 2 (DE3) after induction with IPTG. The culture (whole cells) was centrifuged, and the resulting pellet was sonicated (inclusion body and sonication supernatant). The inclusion body was denatured with 6 M Gu-HCl and loaded onto a Ni column (pass through), washed (wash), and eluted (Ni elution). Thereafter, scFv was purified by a V3 peptide column (V3 elution) and size exclusion chromatography (gel filtration). The eluted samples were analyzed without and with b-ME (reducing condition). Purified 0.5g, 5G2, and 16G6 scFvs were analyzed with their corresponding IgGs by SDS-PAGE (C). M, size marker.
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added, and the temperature was raised to 379 C. Thereafter, incubation and detection were performed similar to a standard neutralization assay.
(iii) Post-attachment naturalization assay using SOS viruses (SOS assay): TZM-bl cells were plated in 96-well plates and incubated overnight for attachment. Then, the amounts of the SOS JR-FL or SOS JR-FL L175P virus corresponding to the titer yielding approximately 200,000 RLU were added with Polybrene (50 mg/ml) to each well. After incubations for 15, 60, or 120 min, the medium was replaced to remove any unbound viruses. Serial dilutions of IgGs and scFvs were added to the wells, and the plates were incubated for 1 h at 379 C. The wells were treated with 5 mM dithiothreitol for 10 min to cleave the disulfide bond between gp120 and gp41. The medium was changed, and incubation and detection were performed similar to a standard neutralization assay.
RESULTS
Production and purification of anti-V3 scFvs: Plasmids expressing 0.5g, 5G2, or 16G6 scFvs were constructed by connecting the variable regions of heavy and light chains with a linker (GGSSRSSSSGGGGSGG GG), and the plasmids were transformed into E. coli strain Rosetta 2 (DE3). The scFv proteins were expressed following IPTG induction (Fig. 1A and B, lane  1) . We used an in vitro refolding process to purify scFvs from the inclusion body in E. coli (Fig. 1A and B, lanes  2 and 3) . The observed smear of bands in SDS-PAGE and western blotting analyses of the eluents from Niaffinity chromatography suggested the presence of a multimeric form (Fig. 1A, lane 6) and dimer (60 kDa) of scFv (Fig. 1B, lane 6) . To further purify monomeric scFvs, we introduced an additional step using V3 peptide-affinity chromatography, which yielded a multimer-free monomeric band of scFv (Fig. 1A and B,  lanes 8 and 9) .
Finally, after a purification step using size exclusion chromatography, we obtained monomeric 0.5g scFv, as shown by the presence of a single band (Fig. 1A and B, lanes 10 and 11). The procedure used for 5G2 and 16G6 scFv purification was very similar to that used for 0.5g scFv purification (data not shown). We obtained monomeric 0.5g, 5G2, and 16G6 scFvs as a single band prepa- 
1C).
Binding activity of anti-V3 antibody fragments: The binding activity of anti-V3 IgG, Fab, and scFv was compared by SPR analysis using biotin-conjugated V3 peptides ( Table 1 ). The K D value of the 0.5g scFv and Fab were 2.8-and 2.2-times higher, respectively, than the K D value of the corresponding IgG. Similarly, the K D value of 5G2 scFv was 4.0-times higher than that of the 5G2 IgG. These results suggest that the binding activity of these antibody fragments might be slightly reduced compared with that of their corresponding full-length antibodies. However, we found that 16G6 IgG and 16G6 scFv have similar binding activity. Notably, the binding activity of 0.5g and 5G2 IgGs was approximately 100 times higher than that of 16G6 IgG (Table  1 ). These data indicate that the anti-V3 scFvs generated from E. coli maintained comparable binding activity against anti-V3 peptides, although the binding activity of scFvs was not quite as high as that of their IgG counterparts.
Broad and potent neutralization by V3 scFvs: To compare the neutralization activity of our scFvs and their corresponding IgGs, single round neutralization assays were performed against a panel of laboratoryadapted and primary HIV-1 strains of subtype B by using TZM-bl cells as a target ( Table 2 ). The tier 1 strains, SF162, Bal, and 6535.3 (SVPB5), and JR-FL L175P , which is a neutralization-sensitive mutant of JR-FL, were sensitive to neutralization by 0.5g, 5G2, and 16G6 IgG, as indicated by their low IC 50 values. The IC 50 values of the scFvs against these neutralization-sensitive strains were higher than those for their corresponding IgGs, suggesting that the neutralization potencies of 0.5g, 5G2, and 16G6 scFvs are less than those of the 0.5g, 5G2, and 16G6 IgGs. In contrast, the neutralization activity exerted by scFvs against tier 2 and 3 strains of HIV-1, which are relatively resistant to neutralization, was more potent. The IC 50 values of 0.5g scFv against 89.6, YU2, JR-FL, QH0692.42 (SVPB6), PVO.4 (SVPB11), and WITO4160.33 (SVPB18) were less than those of 0.5g IgG, although 0.5g IgG was more potent against REJO4541.67 (SVPB16) than 0.5g scFv. Moreover, 0.5g scFv neutralized SC422661.8 (SVPB8), TRO.11 (SVPB12), AC10.0.29 (SVPB13), To compare the extent of IgG and scFv neutralization coverage, we calculated the percentage of 17-19 subtype B isolates of HIV-1 strains that are neutralized by 0.5g, 5G2, and 16G6 scFv or IgG (Fig. 2) . The 0.5g scFv neutralized 17 of the 19 tested strains (89z), whereas only 11 of the 19 strains were neutralized by 0.5g IgG (58z). The 5G2 scFv neutralized 10 of the 17 tested strains (59z), while its IgG counterpart neutralized only 8 of the 17 strains (47z). In contrast, 16G6 IgG and scFv neutralized the same number of strains. The percentage of strains that could be neutralized at a level of IC 50 of ＜10 mg/ml was 74z for the 0.5g scFv as compared with 16z observed for its IgG counterpart and 30z observed for the 5G2 scFv as compared with 18z for its IgG counterpart (Fig. 2) . In summary, a marked improvement in the coverage and potency of neutralization was observed for 2 anti-V3 scFvs as compared with their IgG counterparts.
Based on its high coverage and potent neutralizing activity, we focused on testing the neutralization ability of 0.5g scFv against infectious T/F viruses (Table 3) . Four T/F strains (WITO, CH058, RHPA, and TRJO) of 6 were efficiently neutralized by 0.5g scFv with lower IC 50 values than those of its IgG counterpart. In contrast, CH040 and CH077 were resistant to neutralization by either 0.5g IgG or scFv because their V3-tips (GPGK and GALR, respectively) were not recognized by 0.5g. Taken together, these data indicate that 0.5g scFv induces broad and potent neutralization of HIV-1 subtype B isolates.
Post-attachment neutralization by scFv: To further analyze the mechanism of efficient HIV-1 neutralization Fig. 3 . Post-attachment neutralization activity assessed using SOS JR-FL virus. Post-attachment neutralization activity levels of 0.5g, 5G2, and 16G6 IgGs (A) and scFvs (B) were examined using SOS assays. SOS JR-FL virus, in which gp120 and gp41 are connected with a disulfide bond, was incubated with TZM-bl cells for 15 (◆), 60 (■), or 120 min (△) to allow virus-cell attachment. The data are presented as the means and SDs from quadruplicate samples. Inhibition assays using SOS JR-FL virus were performed 3 times, and representative results are shown. The statistical significance of the differences in IgG or scFv neutralization at 50 mg/ml with negative control (0z inhibition) individuals was calculated using a Student's t-test ( ** , P ＜ 0.001, * , P ＜ 0.05).
by scFv, we employed 2 methods to evaluate postattachment neutralization. We first used TRN assay in which we incubated the viruses and target cells at 49 C for attachment before adding NAbs. We observed that 0.5g scFv retained its neutralizing activity against JR-FL 175P , 89.6, YU2, JR-FL, SC422661.8 (SVPB8), AC10.0.29 (SVPB13), and RHPA4259.7 (SVPB14) strains in the TRN assay at levels comparable with those seen in conventional neutralization assays (Table 4 ). In contrast, 0.5g IgG failed to neutralize the same viral variants in the TRN assay (Table 4 ). THRO4156.18 (SVPB15) was resistant to neutralization by 0.5g IgG and scFv in both assays because of mutation in its V3-tip (GPGG), which is not recognized by 0.5g. Additionally, 5G2 scFv also neutralized the JR-FL strains more efficiently than 5G2 IgG in our TRN assay. The TRN assay data suggest that the anti-V3 scFvs neutralize cellattached viruses whose gp120 has already encountered cell surface CD4. We observed neutralization by all tested IgGs and scFvs (0.5g, 5G2, and 16G6) in the TRN assay of only one strain, namely, the JR-FL L175P mutant ( Table 4 ). The data suggest that the JR-FL L175P mutant V3 epitope is accessible not only for scFv but also for IgG, even after attachment of viruses to target cells. Next, we evaluated the post-attachment neutralizing activity of anti-V3 scFv and IgG by SOS assays using Env mutants with a disulfide bond between the gp120 and gp41 subunits (Fig. 3, 4A and B) (20) . Target cells were pre-incubated with SOS JR-FL or SOS JR-FL L175P virus for 15, 60, or 120 min, followed by the addition of scFv or IgG. After 1-h incubation with scFV or IgG, the disulfide bond between gp120 and gp41 was cleaved by the addition of dithiothreitol, and the samples proceeded to the fusion step. We observed that 0.5g scFv neutralized SOS JR-FL at 50 or 10 mg/ml after pre-incubation of the virus and cells for 15 or 60 min, but not after pre-incubation for 120 min (Fig. 3B, P ＜ 0.05) . Similar data Fig. 4 . Post-attachment neutralization activity assessed using SOS JR-FL L175P virus. Post-attachment neutralization activity levels of 0.5g, 5G2, and 16G6 IgG (A) and scFv (B) were examined using SOS assays. SOS JR-FL L175P virus, in which gp120 and gp41 are connected with disulfide bonds, were incubated with TZM-bl cells for 15 (◆), 60 (■), or 120 min (△) to allow virus-cell attachment. The data are presented as the means and SDs from triplicate or quadruplicate samples. Inhibition assays using SOS JR-FL L175P virus were performed 3 times, and representative results are shown. The statistical significance of the differences in IgG or scFv neutralization at 50 mg/ml with negative control (0z inhibition) individuals was calculated using a Student's t-test ( ** , P ＜ 0.001, * , P ＜ 0.05).
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were obtained for 5G2 and 16G6 at the highest tested concentration (50 mg/ml) of scFvs, which showed comparable levels of neutralization against SOS JR-FL when the target cells and viruses were pre-incubated for 15 or 60 min ( Fig. 3B , P ＜ 0.05). In contrast, the IgG counterparts of these scFvs failed to neutralize the SOS JR-FL strain under any of the tested conditions (Fig. 3A) . To investigate the mechanism responsible for reduced post-attachment neutralizing activity of scFv after preincubation for 120 min, we constructed SOS JR-FL L175P , which exposes its V3 epitope even after attachment to target cells. Both IgGs and scFvs from 0.5g, 5G2, and 16G6 neutralized the SOS JR-FL L175P strain after 15-min incubation ( Fig. 4A and B, P ＜ 0.05). Reduction in the levels of neutralizing activity was observed in a timedependent manner for all the tested IgGs and scFvs. Taken together, the data suggest that the V3 epitope is not available after 60 min of pre-incubation, perhaps because of the attachment of V3 to its co-receptor on the target cells.
The results from our 2 post-attachment neutralization assays indicate that anti-V3 scFv can neutralize HIV-1 even after the attachment of the virus to the target cells. The reduction in the level of scFv neutralizing activity after the viruses and cells were left to attach for 120 min suggested that the interaction of the V3 loop with its coreceptor is completed during this timeframe.
DISCUSSION
In this study, we produced 3 scFvs from anti-V3 MAbs and found that one of the scFv (0.5g scFv) had an unexpectedly broad and potent neutralizing activity against primary HIV-1 isolates, including tier 2 and 3 classes of subtype B. The enhancement in the neutralizing activity of scFvs can be explained, at least in part, by its post-attachment neutralization activity.
The time-dependent decrease observed in post-attachment neutralization during the 120-min pre-incubation period of SOS JR-FL viruses with the target cells may have an important implication for V3-loop post-attachment function. During the incubation of SOS JR-FL with target cells, gp120 interacts with CD4, and subsequently, with its co-receptors (CCR5). Based on our observation of time-dependent reduction in post-attachment neutralization by scFvs, we estimated the period required for this interaction to be less than 120 min. In accordance with our observations, a previous study by Binley et al. also suggested that interaction of the V3-loop with its co-receptor occurred within 120 min, based on the results of an SOS assay (35) . In contrast, the bridging sheet, which is another site of co-receptor binding and overlaps with the epitope recognized by CD4i MAbs, remains available for CD4i-scFv even after 120 min of incubation (20) . However, we further confirmed the significant decrease in post-attachment neutralization after 120 min by using SOS JR-FL L175P , a virus that is unusual in its susceptibility to neutralization by IgG, not just scFv, after gp120-CD4 binding. An interaction between the V3-loop and co-receptor (CCR5) is expected to abrogate the neutralization by scFv after 120 min of incubation. Additionally, the translocation of V3-loop by the catalytic activity of protein disulfide isomerase during the entry process may be involved in the loss of postattachment neutralization at 120 min (37) .
We observed differences in the neutralization activity of the 3 tested anti-V3 scFvs. Of the 3 clones selected for constructing scFvs, 2 had reactivities restricted to subtype B viruses harboring V3-tip sequences of 315R. The genes involved to the 2 MAb clones 0.5g and 5G2 are the same (the VH3-30 gene for VH and the VK2-28 gene for VL), although the lineages of the 2 clones differ. In contrast, the MAb 16G6 uses the VH5-51 gene and the llight chain, which were previously reported as the preferential genes used by anti-V3 antibodies with crosssubtype reactivity (38) . The 16G6 MAb reacted not only with HIV-1 harboring the V3-tip sequence 315R, but also with HIV-1 harboring the V3-tip sequence 315Q, which is indicative of a non-subtype virus (11) . Surprisingly, extensive cross-neutralization was observed for the 0.5g scFv but not for the 16G6 scFv. Recently, Zolla-Pazner et al. reported that the V3-loop is metastable in the envelope trimer on the virion surface, flickering between states in which V3 is either occluded or available for binding to chemokine receptors and to anti-V3 antibodies (7) . Therefore, it is conceivable that the V3 loop remains in the meta-stable state even after gp120-CD4 interaction. Consequently, the high binding affinity observed for 0.5g scFv (K D ＝ 3.75 nM) is required for its extensive cross-neutralization.
Based on its broad and potent neutralizing activity against HIV-1, we recommend that 0.5g scFv be further developed for therapeutic and/or preventive strategies. We also reported that passive transfer of anti-V3 MAb KD-247 successfully suppressed HIV-1 viral load in vivo (16) . Given the recent studies showing that anti-V3 antibodies exert immune pressure on circulating and transmitted viruses and may play a role in reducing the infection rate in both adults and infants born to infected mothers, strategies based on 0.5g scFv or other anti-V3 antibodies could be particularly effective (7, 11, 19, 29, 39) . In addition, combination of 0.5g scFv with certain CD4-mimetic compounds may deserve further investigation as the combination of KD-247 with certain CD4-mimetics markedly enhances the neutralization/binding activity in vitro (40) . However, further studies are needed before scFvs can be used in clinical settings, such as those determining the safety and stability of scFv in vivo. Despite potential challenges, the lower cost of production, compared with the IgG counterparts, is one major benefit of scFvs. Therefore, future studies should assess the in vivo activity of 0.5g scFv, for use in antiviral therapy by intravenous administration or in preventive strategy as a component of a microbicidal preparation.
